- Home
- OPT vs CATX Comparison
OPT vs CATX Comparison
Compare OPT & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- CATX
- Stock Information
- Founded
- OPT 1984
- CATX 1983
- Country
- OPT Australia
- CATX United States
- Employees
- OPT N/A
- CATX N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- CATX Medical/Dental Instruments
- Sector
- OPT Health Care
- CATX Health Care
- Exchange
- OPT Nasdaq
- CATX Nasdaq
- Market Cap
- OPT 767.9M
- CATX 782.7M
- IPO Year
- OPT 2020
- CATX N/A
- Fundamental
- Price
- OPT $3.60
- CATX $3.31
- Analyst Decision
- OPT Strong Buy
- CATX Strong Buy
- Analyst Count
- OPT 1
- CATX 9
- Target Price
- OPT $12.00
- CATX $17.25
- AVG Volume (30 Days)
- OPT 9.2K
- CATX 1.5M
- Earning Date
- OPT 08-30-2024
- CATX 02-12-2025
- Dividend Yield
- OPT N/A
- CATX N/A
- EPS Growth
- OPT N/A
- CATX N/A
- EPS
- OPT N/A
- CATX N/A
- Revenue
- OPT $261,859.00
- CATX $1,557,000.00
- Revenue This Year
- OPT N/A
- CATX N/A
- Revenue Next Year
- OPT $46,864.64
- CATX N/A
- P/E Ratio
- OPT N/A
- CATX N/A
- Revenue Growth
- OPT N/A
- CATX N/A
- 52 Week Low
- OPT $1.79
- CATX $2.70
- 52 Week High
- OPT $5.45
- CATX $19.10
- Technical
- Relative Strength Index (RSI)
- OPT 52.65
- CATX 29.30
- Support Level
- OPT $3.15
- CATX $2.70
- Resistance Level
- OPT $3.39
- CATX $3.33
- Average True Range (ATR)
- OPT 0.17
- CATX 0.30
- MACD
- OPT 0.05
- CATX 0.26
- Stochastic Oscillator
- OPT 72.31
- CATX 42.66
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.